Skip to main content
OpenTrials
Completed

NCT Number: NCT03536819

RF Rejuvenation for Pelvic Floor and Vagina

Evaluation of efficacy and safety of the Votiva RF system with the Forma V handpiece for vaginal treatments.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Midwest Plastic Surgery

LaGrange, Illinois, 60525, United States

About this study

This study will evaluate the effects of radiofrequency on pelvic floor strength and the change in associated symptoms through direct measurement and patient reporting. The patients will undergo two separate evaluation appointments then receive two treatments. One group will receive a sham treatment and the other will receive the treatment. The sham group will be offered treatment at the end of the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult females between the ages of 35-75, seeking treatments for pelvic floor relaxation syndrome or atrophic vaginitis, which include but are not limited to: pelvic floor laxity, decreased muscle contraction in the pelvic floor, urinary incontinence, sexual dysfunction.
  • Participants must have an evaluation by the Pelvic Floor Physical Therapists. All participants must have a minimum of 30% below average reading on initial assessment of internal or external pelvic floor contraction in order to be included in the study.
  • Negative PAP smear and pelvic exam done within last 1 year.
  • The patients should understand the information provided about the investigative nature of the treatment, possible benefits and side effects, and sign the Informed Consent Form, (including the permission to use photography).
  • The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other treatment methods in the treatment areas such surgeries,CO2 treatment, other radiofrequency treatments and fillers injections for the last 12 months and during the entire study period.

Exclusion criteria

  • Internal defibrillator, pacemaker, bladder stimulator or any other implanted electrical device anywhere in the body
  • Permanent metal implant in the treatment area
  • History of pelvic floor radiation
  • Any surgery in the treatment area in the last 3 months
  • Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles
  • Pregnancy and nursing
  • Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications
  • Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes, thyroid dysfunction, polycystic ovary and hormonal virilization
  • Any active condition in the treatment area, such as but not limited to open sores, psoriasis, eczema,vitiligo,herpes and rash.
  • History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin
  • Severe concurrent conditions, such as cardiac disorders, sensory disturbances.
  • Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
  • Diseases that may be stimulated by light, such as epilepsy, lupus and urticaria.
  • Any other previous treatments in the vaginal or perineal area, such as CO2 laser or RF performed on the same area.
  • Any surgical procedure in the vaginal area within the past 12 months.
  • Recent tan from sun, sunbeds or chemicals or planned excessive sun exposure.

Treatment and study plan

Votiva

Device

The applicator uses radio-frequency energy to treat the vaginal canal

Primary outcomes

  1. Effect of RF on Pelvic Floor Measured by Intentional Muscle Contraction Using Biofeedback EMS

    Time frame: 3 months

    There is no signal normalization, this measurement tool is used to measure change in Pelvic Floor Muscle function.

    Pelvic floor muscle Contractions amplitude are measured in mV (microvolt)

    • Peak internal Pelvic Floor Contractions (steadily higher scores demonstrate improvement)
  2. Recording of Adverse Events (Safety)

    Time frame: 3 months

    Observation, assessment and recording of reactions

Secondary outcomes

  1. Evaluate Urinary Symptoms Associated With Pelvic Floor Weakness

    Time frame: 3 months

    ICIQ-Subjective assessment of efficacy on Urinary Incontinence symptoms using the International Consultation on Incontinence Questionnaire ( lower scores demonstrate improvement). The ICIQ-UI Short Form is a questionnaire for evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence in men and women in research and clinical practice across the world. Scoring scale: 0-21.

  2. Evaluate Sexual Dysfunction Symptoms Associated With Pelvic Floor Weakness

    Time frame: 3 months

    FSFI - Subjective assessment of efficacy on sexual dysfunction symptoms, using the Female Sexual Function Index 2-36, increasing scores demonstrate improvement)

  3. Evaluate Quality of Life Symptoms Associated With Pelvic Floor Weakness

    Time frame: 3 months

    PFIQ-7 - Subjective assessment of quality of life change using Pelvic Floor Impact Questionnaire, 0-300, lower scores demonstrate improvement

  4. Evaluate Urinary Incontinence Symptoms

    Time frame: 3 months

    QUID - Questionnaire for Urinary Incontinence Diagnosis. QUID- scaled 0-15, larger values indicating worse UI.

  5. Evaluate Sexual Function Associated With Pelvic Floor Weakness

    Time frame: 3 months

    PISQ-12 short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire . PISQ12 score calculator evaluates sexual function in women with urinary incontinence or pelvic organ prolapse. Score 0-48. Higher number demonstrate improvement.

  6. Evaluate Quality of Life With Pelvic Floor Conditions

    Time frame: 3 months

    PFDI-20. Pelvic Floor Distress Inventory . The Pelvic Floor Distress Inventory Questionnaire-20 (PFDI-20) is the short-form version of the Pelvic Floor Distress Inventory (PFDI). It is a health-related quality of life questionnaire for women with pelvic floor conditions. The PFDI-20 is comprised of 3 scales, which include the Urinary Distress Inventory-6 (UDI-6), Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6), and the Colorectal-Anal Distress Inventory-8. Score 0-300 Lower score demonstrate improvement.

Sponsors and collaborators

Lead sponsor

InMode MD Ltd.

Industry

Registry information

Official study title

Radio-frequency Rejuvenation for Pelvic Floor and Vagina

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
May 25, 2018
Registry last updated
Nov 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.